There are currently 844 clinical trials in Phoenix, Arizona looking for participants to engage in research studies. Trials are conducted at various facilities, including Phoenix Children's Hospital, GSK Investigational Site, Mayo Clinic Arizona and Mayo Clinic. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Personalized Approach to Promote Healthy Aging
NCT06734468
Recruiting
The goal of this clinical trial study is to evaluate the impact of a personalized lifestyle intervention on improving healthspan. The primary questions of interest are whether the personalized intervention will result in improvements in muscle function, immune function, and cognitive function in adults aged 50-85 years. Participants will complete baseline assessments, receive an individualized intervention plan for approximately 3 months, and then complete post-intervention assessments. The inte... Read More
Gender:
ALL
Ages:
Between 50 years and 85 years
Trial Updated:
12/12/2024
Locations: Wexford Innovation Center, Phoenix, Arizona +1 locations
Conditions: Aging, Aging, Healthy
Register for Updates
ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND)
NCT05388708
Recruiting
ASCEND researchers are partnering with families of children who receive extracorporeal membrane oxygenation (ECMO) after a sudden failure of breathing named pediatric acute respiratory distress syndrome (PARDS). ECMO is a life support technology that uses an artificial lung outside of the body to do the lung's work. ASCEND has two objectives. The first objective is to learn more about children's abilities and quality of life among ECMO-supported children in the year after they leave the pediatr... Read More
Gender:
ALL
Ages:
Between 14 days and 20 years
Trial Updated:
12/11/2024
Locations: Phoenix Children's Hospital, Phoenix, Arizona
Conditions: Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation
Register for Updates
4D-150 in Patients With Diabetic Macular Edema
NCT05930561
Recruiting
Phase 2 randomized, active-controlled, double-masked, dose-ranging trial in adults with Diabetic Macular Edema (DME).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2024
Locations: Retinal Research Institute LLC, Phoenix, Arizona
Conditions: Diabetic Macular Edema, Diabetic Retinopathy
Register for Updates
Rehydration Efficiency During Ad-libitum Fluid Intake
NCT06414291
Recruiting
It is well established that rehydration with a carbohydrate-electrolyte solution is more effective in comparison to plain water. This is primarily based on the sodium-glucose co transporter, based on which the world health organization has based its oral rehydration solution recommendations. Also, rehydration with a solution that includes sodium and glucose plasma osmolality should not drop as much as it happens during rehydration with water. As a result, we should have higher fluid intake due t... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
12/03/2024
Locations: Interdisciplinary Science and Technology Building 8, Phoenix, Arizona
Conditions: Dehydration
Register for Updates
Ovarian Tissue Cryopreservation
NCT06710769
Recruiting
Ovarian Tissue Freezing For Fertility Preservation In Girls Facing A Fertility Threatening Medical Diagnosis Or Treatment Regimen
Gender:
FEMALE
Ages:
Between 1 year and 25 years
Trial Updated:
11/26/2024
Locations: Phoenix Childrens, Phoenix, Arizona
Conditions: Infertility, Female
Register for Updates
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
NCT03860883
Recruiting
Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with stage II primary invasive cutaneous melanomas (AJCC 8th edition) to determine differences in disease-free survival. A reduction in margins is expected to improve patient quality of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/25/2024
Locations: Mayo Clinic Phoenix, Phoenix, Arizona
Conditions: Cutaneous Melanoma, Stage II
Register for Updates
Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY
NCT04916210
Recruiting
The overall goal of the DISCOVERY study is to better understand what factors contribute to changes in cognitive (i.e., thinking and memory) abilities in patients who experienced a stroke. The purpose of the study is to help doctors identify patients at risk for dementia (decline in memory, thinking and other mental abilities that significantly affects daily functioning) after their stroke so that future treatments may be developed to improve outcomes in stroke patients. For this study, a "stroke... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/25/2024
Locations: Barrow Neurological Institute, Phoenix, Arizona
Conditions: Ischemic Stroke, Intracerebral Hemorrhage, Subarachnoid Hemorrhage, Dementia, Vascular, Mild Cognitive Impairment, Vascular Cognitive Impairment
Register for Updates
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
NCT06431373
Recruiting
The purpose of this study is to determine the safety and efficacy of brepocitinib in participants with active, non-anterior (intermediate, posterior, or pan) non-infectious uveitis (NIU).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/25/2024
Locations: Clinical Trial Site, Phoenix, Arizona
Conditions: Uveitis, Posterior, Uveitis, Intermediate, Uveitis
Register for Updates
Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors
NCT04064359
Recruiting
The purpose of this study is to evaluate OBT076, which is a drug that combines an antibody with an anti-cancer drug. This class of drugs are called Antibody-Drug Conjugates (ADC). Antibodies are normally produced in the human body by the immune system to fight infections but can be designed to target cancer cells and deliver an anti-cancer drug. OBT076 is composed of an antibody that targets the CD205 protein on cancer cells and delivers an anti-cancer drug which can kill them. OBT076 is an "Inv... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/22/2024
Locations: Mayo Clinic, Phoenix, Arizona
Conditions: Solid Tumor
Register for Updates
Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)
NCT05354141
Recruiting
To evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles (EVs), ExoFlo, versus placebo for the treatment of hospitalized patients with moderate-to-severe Acute Respiratory Distress Syndrome (ARDS).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/21/2024
Locations: Direct Biologics Investigational Site, Phoenix, Arizona
Conditions: Acute Respiratory Distress Syndrome, ARDS
Register for Updates
Pompe Pregnancy Sub-Registry
NCT00567073
Recruiting
This Sub-registry is a multicenter, international, longitudinal, observational, and voluntary program designed to track pregnancy outcomes for any pregnant woman enrolled in the Pompe Registry, regardless of whether she is receiving disease-specific therapy (such as ERT with alglucosidase alfa or avalglucosidase alfa) and irrespective of the commercial product with which she may be treated. No experimental intervention is given; thus a patient will undergo clinical assessments and receive standa... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
11/19/2024
Locations: Barrow Neurol Group- Site Number : 840087, Phoenix, Arizona
Conditions: Glycogen Storage Disease Type II (GSD-II), Pompe Disease (Late-onset), Glycogenesis 2 Acid Maltase Deficiency
Register for Updates
A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma
NCT04814108
Recruiting
This is a Phase 2 study to evaluate the clinical activity and safety of ZN-c3 (azenosertib) in adult women with recurrent or persistent uterine serous carcinoma (USC).
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: Honor Health, Phoenix, Arizona
Conditions: Uterine Serous Carcinoma
Register for Updates